Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Jul 15, 2023; 15(7): 1200-1214
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1200
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1200
Table 3 Potential perturbagens of interactive prognostic cuproptosis-related genes
Perturbagen | Moa | Raw_cs | FDR_q_nlog 10 |
Fluconazole | Sterol demethylase inhibitor | 0.79 | 1.03 |
KD-025 | Rho associated kinase inhibitor | 0.77 | 0.95 |
Clofarabine | Ribonucleoside reductase inhibitor | 0.76 | 0.89 |
Tramadol | Opioid receptor agonist, Norepinephrine reuptake inhibitor, Serotonin reuptake inhibitor | 0.76 | 0.89 |
Doxorubicin | Topoisomerase inhibitor | 0.75 | 0.88 |
AXD-5438 | CDK inhibitor | 0.73 | 0.80 |
BRD-K67174965 | Mucolytic | 0.73 | 0.79 |
Faropenem | Lactamase inhibitor | 0.72 | 0.76 |
Clocortolone-pivalate | Steroid | 0.72 | 0.68 |
Ganglioside | Src activator | 0.71 | 0.46 |
- Citation: Yan JN, Guo LH, Zhu DP, Ye GL, Shao YF, Zhou HX. Clinical significance and potential application of cuproptosis-related genes in gastric cancer. World J Gastrointest Oncol 2023; 15(7): 1200-1214
- URL: https://www.wjgnet.com/1948-5204/full/v15/i7/1200.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i7.1200